# Enoxaparin for Preventing the Radical Artery Occlusion After the Transradial Access Hepatic Arterial Infusion Chemotherapy

> **NCT06293287** · PHASE2 · UNKNOWN · sponsor: **Zhongshan Hospital (Xiamen), Fudan University** · enrollment: 156 (estimated)

## Conditions studied

- Radial Artery Occlusion

## Interventions

- **DRUG:** Subcutaneous enoxaparin sodium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06293287
- **Lead sponsor:** Zhongshan Hospital (Xiamen), Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-31
- **Primary completion:** 2024-11-30
- **Final completion:** 2025-01-30
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06293287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06293287, "Enoxaparin for Preventing the Radical Artery Occlusion After the Transradial Access Hepatic Arterial Infusion Chemotherapy". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT06293287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*